Virtus Biotech Clinical Trials EtfBBC
Type
ETF
Peer group
US equity: Healthcare
Net assets
$37.3M
Expense ratio
0.65%
1-year return
+137.2%
3 years, a year
+36.5%
5 years, a year
+2.7%
12-month yield
1.45%
Holdings
125
What it aims to do.
The Virtus Biotech Clinical Trials ETF (formerly, Virtus LifeSci Biotech Clinical Trials ETF) (the Fund ) seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index (the Underlying Index ).
Top 10 holdings.
| Holding | % of fund |
|---|---|
| JOBY Dreyfus Government Cash Manage | 2.28% |
| ERAS Erasca Inc | 2.19% |
| ELVN Enliven Therapeutics Inc | 1.81% |
| TNGX Tango Therapeutics Inc | 1.71% |
| ORKA Oruka Therapeutics Inc | 1.68% |
| SYRE Spyre Therapeutics Inc | 1.64% |
| ALMS Alumis Inc | 1.59% |
| DNTH Dianthus Therapeutics Inc | 1.54% |
| KOD Kodiak Sciences Inc | 1.35% |
| RVMD Revolution Medicines Inc | 1.35% |
More on BBC.
- BBC overview
- BBC holdings
- BBC risk
- BBC costs
- BBC money in and out
- BBC share classes
- Compare BBC with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.